BACKGROUND This review was commissioned by the World Health Organization and
presents a summary of the latest research evidence on the impact of coronavirus disease …

Objectives: Pre-existing or new diabetes confers an adverse prognosis in people with Covid-
19. We reviewed the clinical literature on clinical outcomes in metformin-treated subjects …

С декабря 2019 г. в мире активно распространяется опасное вирусное заболевание-
COVID-19, вызванное новым РНК-коронавирусом SARS-COV-2. Основным …

The impact of overlapping risk factors on coronavirus disease (COVID-19) severity is
unclear. To evaluate the impact of type 2 diabetes (T2D) and obesity on COVID-19 severity …

Background & aims Several observational studies have recently reported the outcomes of
non-insulin anti-diabetic agents (ADA) in patients with T2DM and coronavirus disease 2019 …

Metformin (MTF) occupies a major and fundamental position in the therapeutic management
of type 2 diabetes mellitus (T2DM). Gender differences in some effects and actions of MTF …

Objectives To investigate the association between baseline use of glucose-lowering drugs
and serious clinical outcome among patients with type 2 diabetes. Design Territory-wide …

A dangerous viral disease COVID-19, caused by a new RNA coronavirus SARS-COV-2, has
been actively spreading in the world since December 2019. The main manifestations of this …

Diabetes is the most frequent comorbidity among patients with COVID-19. COVID-19
patients with diabetes have a more severe prognosis than patients without diabetes …

Patients with Covid-19 place new challenges on the management of type 2 diabetes,
including the questions of whether glucose-lowering therapy should be adjusted during …